Amisodin
Alternative Names: PRG-A; PRG-A-05Latest Information Update: 28 Nov 2025
At a glance
- Originator PRG Science & Technology
- Class Small molecules
- Mechanism of Action Superoxide dismutase-1 inhibitors
-
Orphan Drug Status
Yes - Amyotrophic lateral sclerosis
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Amyotrophic lateral sclerosis
Most Recent Events
- 10 Nov 2025 Amisodin receives Fast Track designation for Amyotrophic lateral sclerosis [PO] (In volunteers) in USA
- 01 Oct 2025 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in USA (PO) (NCT07221240)
- 27 May 2025 Pharmacodynamics data from a preclinical trial in Amyotrophic lateral sclerosis released by PRG Science and Technology